Introduction
Infection with the Epstein-Barr virus (EBV), a ubiquitous oncogenic g-type herpes virus, is implicated in the etiology of several lymphoid and epithelial malignancies, including Burkitt's lymphoma, Hodgkin's lymphoma, nasal NK/T cell lymphoma, nasopharyngeal carcinoma, and a subset of gastric carcinomas (GCs).
1-3 EBV-associated GC (EBVaGC) is defined as the monoclonal proliferation of carcinoma cells with latent EBV infection, which can be demonstrated by in situ hybridization targeted at EBV-encoded small RNA (EBER). In EBVaGC, virtually all cancer cells contain EBV DNA sequences, and the EBV terminal repeat sequences have uniform lengths, implying that the tumor can arise from a single EBV-infected cell and that the EBV genome persists during malignant transformation and proliferation. 4, 5 About 10% (1.3% to 20.1%) of GCs are EBV-positive; [6] [7] [8] however, the prognostic effect of EBV positivity in GC is controversial.
While some studies have shown significantly better prognosis in EBVaGC than in EBV-negative GC (EBVnGC), [9] [10] [11] [12] other studies failed to observe this prognostic difference. 13 20 There was no significant correlation between age and EBV positivity. 16, [19] [20] [21] Several studies have found an apparently higher incidence of synchronous multiple carcinomas in EBVaGC than in EBVnGC. [22] [23] [24] Smoking is one of the risk factors of EBVaGC. 25 The influence of Helicobacter pylori infection on EBVaGC emergence is controversial. per tissue section, were classified as CA (Fig. 1C) . 19 The prognosis was affected by the intensity and pattern of the inflammatory response. Among them, LELC cases had the best prognosis, followed by patients with CLR, who, in turn, had better survival rates than those with CA. Several studies found that EBVaGC is often accompanied by more extensive infiltration of CD8-positive cytotoxic T cells and a higher number of mature dendritic cells than EBVnGC. 14, 15, [30] [31] [32] [33] Infiltrating immune cells at least partially contribute to antitumor immunity by promoting the eradication of EBV-positive malignant cells. 19, 31, 34 However, neither the mechanisms by which carcinoma cells are killed nor the biochemical cascades that allow them to evade the host immune response during tumor development and progression have been properly determined.
Cytokines
In 1998, transplantable human EBVaGC was designed and propagated in mice with severe combined immunodeficiency. 35 The only cytokine gene that showed markedly higher expression in EBVaGC tumor strains compared to EBVnGC strains was IL1B that encodes interleukin-1b (IL-1b). 36 IL-1b recruits numerous nonspecific lymphocytes to prevent direct contact between EBVspecific cytotoxic T cells and tumor cells. compared to that of patients with EBVnGC. expression has been reported in several human malignancies. [41] [42] [43] [44] [45] [46] [47] [48] [49] [50] [51] [52] [53] [54] [55] Although some controversy remains, many studies have shown that PD-L1 overexpression is associated with worse prognosis in many types of cancer. 56 Two published studies of GC used immunohistochemical analysis and showed that abnormally high levels of PD-L1 are associated with poor prognosis, 41, 42 while a recent study with 243 patients with curatively resected GC showed better disease-free survival and overall survival in patients with PD-L1
expression. 57 In TCGA data, PD-L1/2 expression was elevated in
EBVaGCs, in which IL-12-mediated signaling signatures induced robust immune cell presence. 18 When coupled with the evidence of PD-L1/2 overexpression, this finding adds rationale for testing immune checkpoint inhibitors in EBVaGC. 
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